Wrapping up the year, current discounts, and growth in 2023...
As we head toward the end of 2022, the cell and gene sector is still abuzz with activity and new discoveries. Announcements of new clinical trials and recent breakthroughs that are advancing cell therapy beyond oncology are creating a lot of excitement for what’s to come in 2023. Many industry insiders are anticipating that 2023 could bring the first-ever approval of a CRISPR gene-editing therapy.
At AllCells, we invest in continuous improvement across our products and services to provide comprehensive solutions for our clients across the industry. Our quarterly update is a great opportunity to highlight some of the exciting new promotions, blogs, upcoming conferences, and more! Find out what’s new at AllCells as we head toward the end of 2022 and look ahead to 2023.
What's New
The opening of the new AllCells’ Houston, Texas donor facility greatly increases apheresis capacity and grows our network as a whole, providing scalable access to 10,000+ recallable donors.
AllCells is offering up to 80% off bulk PBMCs from now until December 22nd. Take advantage of this great opportunity to stock up on high-quality mononuclear cells to advance your research!
Recommended by LinkedIn
Isolated CD34+ stem cells from AllCells’ single dose, G-CSF Mobilized Leukopaks are collected on days 5 and 6 from healthy donors. Take 40% off select products for a limited time!
As a Discovery Life Sciences company, AllCells’ donor expertise and consultative approach work synergistically with Discovery’s suite of hyper-annotated™ biospecimens, prospective studies, and integrated multi-omics analytics.
Coming Soon
AllCells will be at Advanced Therapies Week in January 2023. Our Chief Technical Officer, Dominic Clarke Ph.D. will be part of the opening plenary discussion. We hope to see you there!